{"links":{"html":"https://www.erudio.com/reports/mapkeeper-301-nct07562152","json":"https://www.erudio.com/reports/mapkeeper-301-nct07562152.json","markdown":"https://www.erudio.com/reports/mapkeeper-301-nct07562152.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"mapkeeper-301-07562152"}},"request":"https://www.erudio.com/contact?report=mapkeeper-301-07562152"},"offer":{"cited_commentary_sources":37,"verified_hcp_statements":138,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":8,"optional":true,"price_per_verified_person_usd":15,"price_usd":120,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"mapkeeper-301-nct07562152"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=mapkeeper-301-07562152","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/mapkeeper-301-nct07562152","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-01T16:40:37.419898Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":0},"aspects":[{"claim_count":16,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":8,"title":"Primary endpoint: Overall Survival"},{"claim_count":11,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":11,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":2,"title":"Population and setting"},{"claim_count":14,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":11,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":6,"title":"Safety and tolerability"},{"claim_count":14,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":10,"title":"Design and conduct"},{"claim_count":14,"coverage":"discussed","id":"A1","source_count":9,"title":"Pulsatile MEK rationale and earlier clinical development"},{"claim_count":23,"coverage":"discussed","id":"A2","source_count":2,"title":"Molecular work-up and germline-directed treatment pathways"},{"claim_count":6,"coverage":"discussed","id":"A3","source_count":2,"title":"Fitness, treatment burden, preferences and supportive care"},{"claim_count":13,"coverage":"discussed","id":"A4","source_count":8,"title":"Post-progression fitness and sequencing with RAS-directed alternatives"},{"claim_count":18,"coverage":"discussed","id":"A5","source_count":12,"title":"Regional access, recruitment, follow-up and timing"}],"counts":{"cited_sources":37,"claims_by_expression_type":{"comparison":10,"experience":6,"interpretation":27,"opinion":42,"question":7,"restatement":11,"uncertainty":6,"unspecified":29},"claims_by_kind":{"interpretation":1,"source_observation":137},"clinician_statements":64,"evidence_units":89,"findings":12,"organisational_accounts":8,"people_cited":14,"people_identity_verified":8,"people_total":14,"screened_sources":89,"verified_claims":138},"findings_index":[{"id":"F1","structure":{"claims":10,"claims_by_group":{"comparisons":3,"experience":0,"questions":0,"restated":1,"views":6},"has_counterview":true,"limitations":2,"links":{"context":0,"support":12},"ma_question":true,"named_voices":7,"passages":9,"sources":8,"sources_by_kind":{"commentary":7,"media":1}},"title":"The survival signal attracts enthusiasm, but randomized confirmation remains the adoption threshold"},{"id":"F2","structure":{"claims":10,"claims_by_group":{"comparisons":2,"experience":0,"questions":3,"restated":1,"views":4},"has_counterview":true,"limitations":2,"links":{"context":0,"support":13},"ma_question":true,"named_voices":2,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"The OS–PFS disconnect generates competing explanations, not a settled mechanism"},{"id":"F3","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":5},"has_counterview":true,"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":5,"passages":6,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Favorable tolerability assessments coexist with high-grade toxicity and attribution uncertainty"},{"id":"F4","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":0,"views":6},"has_counterview":true,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":5,"passages":6,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Weight, quality of life and ability to receive later therapy are valued outcomes"},{"id":"F5","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":3,"questions":0,"restated":3,"views":6},"has_counterview":true,"limitations":2,"links":{"context":0,"support":13},"ma_question":true,"named_voices":6,"passages":8,"sources":7,"sources_by_kind":{"commentary":6,"media":1}},"title":"The pulsatile MEK rationale is attractive, but its clinical application remains contested"},{"id":"F6","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":6,"views":2},"has_counterview":true,"limitations":2,"links":{"context":1,"support":12},"ma_question":true,"named_voices":2,"passages":7,"sources":3,"sources_by_kind":{"media":3}},"title":"The first-line comparison sits within several active chemotherapy choices and schedule-dependent toxicity trade-offs"},{"id":"F7","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":1,"views":7},"has_counterview":true,"limitations":3,"links":{"context":0,"support":12},"ma_question":true,"named_voices":2,"passages":8,"sources":2,"sources_by_kind":{"media":2}},"title":"Biomarker-agnostic enrollment does not make early molecular work-up optional in practice"},{"id":"F8","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":5},"has_counterview":false,"limitations":2,"links":{"context":1,"support":5},"ma_question":true,"named_voices":1,"passages":4,"sources":2,"sources_by_kind":{"media":2}},"title":"Germline findings can favor a different initial regimen and a conditional maintenance sequence"},{"id":"F9","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":5},"has_counterview":false,"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":1,"passages":4,"sources":2,"sources_by_kind":{"media":2}},"title":"Patient fitness and preferences can favor less treatment—or supportive care instead"},{"id":"F10","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":1,"views":4},"has_counterview":true,"limitations":6,"links":{"context":0,"support":9},"ma_question":true,"named_voices":7,"passages":8,"sources":8,"sources_by_kind":{"commentary":6,"media":2}},"title":"RAS-directed competition raises sequencing questions and conflicting positioning arguments"},{"id":"F11","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":3,"views":6},"has_counterview":true,"limitations":3,"links":{"context":5,"support":13},"ma_question":true,"named_voices":7,"passages":7,"sources":7,"sources_by_kind":{"commentary":7}},"title":"Recruitment and access enthusiasm should not be mistaken for an efficacy update"},{"id":"F_vogel_phase2a_context","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"has_counterview":false,"limitations":3,"links":{"context":0,"support":2},"ma_question":false,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"A speaker's interest concerns the earlier phase 2a combination study"}],"medical_affairs_question":"Can randomized survival, toxicity and patient-reported outcomes distinguish drug benefit from selection and subsequent-care effects while clarifying which first-line patients would value the trade-off?","sections":{"analysis":[{"id":"section-1","level":2,"title":"1. Enthusiasm is strongest for development; adoption remains conditional"},{"id":"section-2","level":2,"title":"2. The OS–PFS relationship is an unresolved explanatory question"},{"id":"section-3","level":2,"title":"3. Manageable toxicity does not mean no high-grade harm"},{"id":"section-4","level":2,"title":"4. Preserved weight and later-treatment fitness are part of the proposed value"},{"id":"section-5","level":2,"title":"5. Biological plausibility is supported without resolving the right clinical application"},{"id":"section-6","level":2,"title":"6. Alternative first-line chemotherapy and routine schedule modification remain clinically relevant"},{"id":"section-7","level":2,"title":"7. Broad enrollment and individualized molecular work-up are complementary"},{"id":"section-8","level":2,"title":"8. Germline-informed platinum treatment is a distinct competing pathway"},{"id":"section-9","level":2,"title":"9. Treatment intensity is conditional on fitness, priorities and care support"},{"id":"section-10","level":2,"title":"10. Competitive positioning remains conditional on line of therapy and sequence"},{"id":"section-11","level":2,"title":"11. Access, execution and follow-up updates are not efficacy readouts"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":8},{"id":"F2","shared_claims":7},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F11","shared_claims":1}],"id":"T1","label":"Primary endpoint: Overall Survival"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":4}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F6","shared_claims":2},{"id":"F7","shared_claims":5},{"id":"F9","shared_claims":4},{"id":"F10","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":9},{"id":"F8","shared_claims":1},{"id":"F9","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":5},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":3}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":3},{"id":"F5","shared_claims":1},{"id":"F11","shared_claims":4}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-01T16:40:37.419898Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-01T16:52:03Z","record_hash":"72767dbbdcc249325c52a6404d6f082863198670d236ed0fa24531ad34234112","release_hash":"2a10564f1473c802cc95037db711d481fdd9710a56c13f701316d609dd7390cc","report_id":"erudio-nct07562152","run_id":"c5f7ad24-9d2a-4887-baa8-a23b49444c3f","schema_version":"5.0","slug":"mapkeeper-301-07562152","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"MAPKeeper 301 compares atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) with standard chemotherapy for overall survival in metastatic pancreatic ductal adenocarcinoma; discussion centers on randomized confirmation before adoption. The report cites three physicians, including one medical oncologist described in the source as involved in the trial; high-grade toxicity attribution remains unresolved. Can randomized survival, toxicity and patient-reported outcomes distinguish drug benefit from selection and subsequent care, and clarify which first-line patients value the trade-off? The sources reviewed for this edition place the earlier phase 2a atebimetinib plus mGnP results at ASCO 2026.","meta_description":"89 sources screened · 138 verified statements (64 from clinicians verified by NPI or staff page) from 37 sources · 12 findings. Updated Nov 1, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-b406eb4ff3d7417b10c3"],"id":"F2","paraphrase":"A post on X asks whether the earlier cohort resembles MAPKeeper 301 participants and why overall survival diverges from progression-free survival and response.","publication_caveats":["The post author's clinical role is not stated in the sources reviewed for this edition."],"source_channel":"x_thread","source_date":"2026-06-02","title":"The OS–PFS disconnect generates competing explanations, not a settled mechanism"},{"cited_claim_ids":["claim-4f1a0bb0a750056cfc2f","claim-cb737edb71d913e4ef44"],"id":"F7","paraphrase":"A physician on YouTube asks how combined DNA/RNA sequencing compares with other testing methods for finding actionable alterations in metastatic pancreatic ductal adenocarcinoma.","publication_caveats":["The question concerns treatment planning, not a testing requirement established for MAPKeeper 301."],"source_channel":"youtube","source_date":"2026-07-14","title":"Biomarker-agnostic enrollment does not make early molecular work-up optional in practice"}]},"publication":{"approved_at":"2026-11-01T16:52:03Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":89},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a remark on first-line pancreatic cancer efficacy evidence and planned pivotal trial initiation.","Not yet captured in this edition: a remark on the start of patient dosing in the pivotal metastatic pancreatic cancer trial.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","103 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed do not represent all HCPs or all public discussion. Some relevant passages were not fully assessed, and unnamed references or wording variants may be missing; absence of a view is not evidence that nobody expressed it.","The material mixes documented clinician commentary, authors whose clinical roles are not established, company statements and investment-oriented interpretations. These categories cannot be pooled into an HCP consensus.","Similar posts, reposts and substantially overlapping educational videos are not independent opinions. A confirmed identifier or professional association does not increase the truth or evidentiary weight of a view.","No exact-trial outcomes publication or protocol was available. Formal eligibility detail, amendments and regulatory assertions could not be independently checked from those documents.","Most numerical efficacy and safety discussion concerns earlier-phase studies, with historical comparators and differing cohorts, follow-up or reported values. It must not be presented as MAPKeeper 301 results.","Some July educational-video comments have no identified speaker. Attribution in a separate upload does not establish who spoke those passages.","Accounts differ in response estimates, safety attribution and anticipated trial timing. The report preserves those differences rather than choosing a preferred version.","Approval characterizations and unusual drug names are preserved as the authors expressed them. They are not independently confirmed regulatory facts.","Mechanistic explanations for weight preservation, post-progression survival and failures of other development programs remain attributed hypotheses, not established causal findings."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":2,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":32,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":37},"count":37,"evidence_window":{"end":"2026-10-30","start":"2026-01-07"},"retrieval_snapshot":"2026-11-01T15:09:48.340628Z","timeline":[{"count":5,"week":"2026-W02"},{"count":1,"week":"2026-W04"},{"count":1,"week":"2026-W10"},{"count":1,"week":"2026-W16"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W21"},{"count":6,"week":"2026-W23"},{"count":1,"week":"2026-W24"},{"count":2,"week":"2026-W25"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W29"},{"count":1,"week":"2026-W32"},{"count":3,"week":"2026-W35"},{"count":1,"week":"2026-W38"},{"count":2,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":1,"week":"2026-W43"},{"count":7,"week":"2026-W44"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07562152:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07562152:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-2ldgzgkb5gn7kfn35avzn7ai-3mlvb4mra552y","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mwozonjdi22p","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-eaeknthaikc5ro5t7qdgyet2-3maaxcqnqbc2d","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3ma7ku25r272o","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3mmfctqsstf25","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3mnz4rswnwg2r","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3myrmnyu43e2p","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ry3wmi3k2ygwgfstao5tw6wg-3mo3ygeb5ax26","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-t5kvjzece3qgysdmwvem36xv-3muuy63wjgf24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-t5kvjzece3qgysdmwvem36xv-3myt6lelvrb2f","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7421160617644011520","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7480011170213457920","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:056a72","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2001407242080284848:bbeea776-d529-453f-9485-88504c8dc5d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2001663813184032894:5841a94b-92af-40c0-ad9a-252dc5341598","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009007348631716287:a20660ed-249d-4ec2-bec5-a0054bc1bd7d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009007606795518275:b8225a9e-b0bd-4087-a633-ac02e002623e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009043370094809219:cb4265c8-133b-4143-8483-9bf5981593e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009183109493793145:5fe7fe4d-4be2-43f7-9f82-07d39bcd6164","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009287974844838083:e8c53a32-d86c-488b-8720-3fa38a5302ab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2029905324900069449:4979355f-91b9-4cdb-97bc-837ff0305052","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2029908392962113994:056f51d6-91e0-48ce-b78c-286aeed5ff92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2029965383139217814:8dd7ca0f-6e7c-4db4-a177-0b8400fc0adc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2044861797698609338:20a22a98-2f6e-402d-a3de-00e3019eb3a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055250874855760255:092c0e07-3601-40de-af83-51cc4b25c538","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055253595071681005:86fed072-eb22-46e7-964c-cd15d0cd51bc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055266209386402096:e0719843-1706-4d0d-8770-588147d27a49","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055266413166707123:e92329d5-8de5-428b-88d8-41d0f40a7319","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055271275254120806:bd192122-1310-411f-8c7b-d1e8161a0c4e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057795735869911268:72481578-73f6-4ad8-93f1-e7ace9f20e5b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057801450986602887:b7f46421-8ad1-4140-a698-a79aa8de587d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057854275779502141:ec5fc2e9-6788-4b02-8143-dcd86db06fdc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061417520264032758:eb5f9114-b919-4394-a9e5-f506e0467327","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061523182566146300:9bf63fd2-baf9-47d2-8248-1e02e965c6ae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061523287038116147:508de3c8-bc1e-442c-8200-4b1bb5651b2b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061525862575390756:74eecc6f-e524-44e0-93a9-e02181fb7c08","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061812896883949707:7f4be7ca-7d63-42a3-9411-ae91a486b167","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061925062874395098:b6fbf21a-1ee1-4c92-99a1-4d91c316e395","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061925635652723137:db7eb622-6444-4910-bb91-104eee5b40f6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061927342885265591:79c58da0-fed2-4233-b71e-125bd83a90e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062249723394732035:d4eacd91-44c3-40f5-9268-ac11d46d30e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065038132462924037:c91d1980-dcf8-4bb3-a73a-fd47c5eec9d1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065041544114262220:5fbec821-0305-4581-aef1-00218b710d2d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065050418053324873:f9a56bf6-f996-47a0-9678-f9442cffeab3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065072353688862904:34572b43-e3d4-4695-966d-e9f199415ad0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065083989988344028:bd1e19bc-e71b-4b21-8001-408a8540f42e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065088737550446944:f4d49fc0-1b21-4bd9-a644-8f56c484aea4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065101896893796472:c13f70ad-f6db-4bdd-ab14-09470934ef90","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065868606101934112:e61f9752-c52c-4b06-a838-a88612c2e818","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066597865233813663:dc769903-d6a6-442a-a66c-21cb65e4f617","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066623770228408447:bf95e3fd-cfba-47f8-a855-904fc82cd13a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2067579399830995038:a084949a-d573-44b0-82de-93a2380bee64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2084979277099843911:ef58803d-d57d-40da-9332-7099ab8f661e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2084986740729593906:20a6431a-18a5-47d5-b78d-be1cbe6d89e0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092724493642801614:075c0373-9fa1-470c-97f0-e95810ac28cc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092953381019046000:e2c5d6bd-4073-493a-b2dd-c76d20c7a928","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093005710699217255:748dc9cc-709e-4ff9-9d1a-ca7755bc4a50","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094742074138546553:422d9e23-330a-4b50-a55c-7856a9498fef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099467620026044824:fe94b6c2-0fa6-4e35-b685-20210ac6823c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099559123440329113:db9ce4a4-6d9c-4679-b663-00e697d033a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100253445118660669:ebc3e5b8-dab8-407b-8d9b-f21eb08301cf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100751668057149681:1bb72309-3e18-49b2-ba0b-757e4a281500","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102065928741568569:474ab72b-e078-4369-8bd8-f85b94f8202c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102069363238945140:cdf05614-4a45-4655-8a62-c14ae1fec02f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103152585683165421:c0df85f7-ac18-4ec4-b0d6-f264a38980c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103154011129970694:33dfeb89-2f46-4a38-af77-7ee8af30c297","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105083873168158945:92a402ac-053f-4185-8216-39c931943117","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107166105768718843:30f57399-3167-440b-906b-c28315e752c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107166951147483345:77848844-f127-4ac6-a1c5-70c7ae98f107","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107865063428071505:fd6103bf-133d-4a85-828b-b64558f7f99f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110037893364289968:0c3fae19-f0a5-4e97-bc86-55c698ed88a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110755357295284684:da03f76c-14c7-4a96-b774-db30b1ee29be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110770200630927535:0cb99af5-0c42-465b-becc-9e0a48c6968d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113661835916288458:ddf30335-0f90-4d46-a5d9-db0da8f3f3fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114681137507557711:18cde268-1874-4939-92cc-3f05167daaa8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114704301327065305:31a4c982-ba3b-4fb3-a1de-646977bb3375","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114759164287386047:c84d7017-86fb-4f4b-bd7a-6ab768db0488","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114764093076697493:a930302b-883e-4c5d-beed-82080bfd4a2a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114769327757148316:7b9dd7c5-7e4f-4c6c-9a4d-5ccd997fa4d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114905452106412541:1e66aa14-1a60-4d0a-8830-403762c5318d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115428400361845095:d3f06603-4a9c-4312-a609-098f8fe769bc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115919969393267033:7132a4c3-fef7-4a81-83e5-dd0a1d35d7bb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115933893501366659:30a0b45a-0c1b-4fad-a2ae-af96c59cba1e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116124477100568920:699db2b5-a030-493f-b609-371e9699a618","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116127773894803462:aa977b86-cd42-460d-abe0-dc82ccf10646","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116187245526786355:b2bf2e6c-656f-4618-b6b1-14b1846615b9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116191181793087499:a9108e40-22fd-4cad-ac1f-ade8e31feff1","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:E3IKyMc1ZdE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:S8qbX7qMXlE","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":10,"linkedin_post":2,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":74,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":89},"count":89,"evidence_window":{"end":"2026-10-30","start":"2025-12-17"},"retrieval_snapshot":"2026-11-01T15:09:48.340628Z","timeline":[{"count":4,"week":"2025-W51"},{"count":5,"week":"2026-W02"},{"count":1,"week":"2026-W04"},{"count":3,"week":"2026-W10"},{"count":1,"week":"2026-W16"},{"count":6,"week":"2026-W20"},{"count":4,"week":"2026-W21"},{"count":9,"week":"2026-W23"},{"count":10,"week":"2026-W24"},{"count":3,"week":"2026-W25"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W29"},{"count":2,"week":"2026-W32"},{"count":3,"week":"2026-W35"},{"count":2,"week":"2026-W36"},{"count":5,"week":"2026-W38"},{"count":4,"week":"2026-W39"},{"count":2,"week":"2026-W40"},{"count":4,"week":"2026-W41"},{"count":3,"week":"2026-W42"},{"count":1,"week":"2026-W43"},{"count":15,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: atebimetinib","status":"unmapped"},{"reason":"Unmapped registry intervention: gnp","status":"unmapped"},{"reason":"Unmapped registry intervention: mgnp","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Pancreatic Cancer","status":"unmapped"},{"reason":"Unmapped registry condition: Pancreatic Cancer Metastatic","status":"unmapped"},{"reason":"Unmapped registry condition: PDAC","status":"unmapped"},{"reason":"Unmapped registry condition: PDAC - Pancreatic Ductal Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Pancreatic Ductal Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Pancreatic Adenocarcinoma Metastatic","status":"unmapped"},{"reason":"Unmapped registry condition: Pancreatic Ductal Adenocarcinoma (PDAC)","status":"unmapped"},{"reason":"Unmapped registry condition: Pancreatic Adenocarcinoma","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"MAPKeeper 301","aliases":["MAPKeeper 301","Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)"],"brief_title":"Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Pancreatic Cancer","Pancreatic Cancer Metastatic","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma","Pancreatic Adenocarcinoma Metastatic","Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Adenocarcinoma"],"display_condition":"first-line metastatic pancreatic ductal adenocarcinoma","display_interventions":[["atebimetinib"]],"enrollment":{"count":510,"type":"ESTIMATED"},"interventions":[{"name":"Atebimetinib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"GnP","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"mGnP","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT07562152","official_title":"A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-06","type":"ESTIMATED"},"primary_endpoints":[{"description":"The OS of participants with atebimetinib in combination with mGnP versus GnP","measure":"Overall Survival","timeFrame":"Up to approximately 2 years"}],"registered_date":{"date":"2026-05-01","type":"ACTUAL"},"registry_last_updated":"2026-10-30","registry_url":"https://clinicaltrials.gov/study/NCT07562152","short_name":"MAPKeeper 301","short_name_basis":"registry_acronym","sponsor":"Immuneering Corporation","start_date":{"date":"2026-06-05","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"IMM1104-301","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}